Manufacturing Challenges & Considerations for Allogeneic Cell Therapy
Hanson Wade Intelligence
The allogeneic cell therapy space has many development and manufacturing bottlenecks which are further compounded by the diversity of cell types, delivery systems and gene editing technologies that are now being pursued in the clinic.
To better elucidate these challenges Hanson Wade Intelligence, our Market Research division, spoke to 15 key opinion leaders within the allogeneic cell therapy space. We summarised their views alongside quantitative insights from our Beacon Adoptive Cell database in this opinion review.
This report aims to provide cell therapy developers with valuable insights on the main allogeneic manufacturing challenges and considerations for optimisation of key stages of development.
An Interview with… Sven Kili, CEO at Antion Biosciences
We asked Sven Kili to share his thoughts on this emerging area of cellular immunotherapy